James M Lonie
Overview
Explore the profile of James M Lonie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brosda S, Aoude L, Bonazzi V, Patel K, Lonie J, Belle C, et al.
Genome Med
. 2024 Jul;
16(1):90.
PMID: 39020404
Background: Oesophageal adenocarcinoma (OAC) is a highly heterogeneous cancer with poor survival. Standard curative treatment is chemotherapy with or without radiotherapy followed by oesophagectomy. Genomic heterogeneity is a feature of...
2.
Belle C, Lonie J, Brosda S, Barbour A
Front Immunol
. 2023 Dec;
14:1330635.
PMID: 38155973
The poor treatment response of oesophageal adenocarcinoma (OAC) leads to low survival rates. Its increasing incidence makes finding more effective treatment a priority. Recent treatment improvements can be attributed to...
3.
Lonie J, Brosda S, Bonazzi V, Aoude L, Patel K, Brown I, et al.
Front Immunol
. 2023 Nov;
14:1220129.
PMID: 37965317
A plateau in treatment effect can be seen for the current 'one-size-fits-all' approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment...
4.
Aoude L, Brosda S, Ng J, Lonie J, Belle C, Patel K, et al.
J Mol Diagn
. 2023 Aug;
25(10):771-781.
PMID: 37544359
For patients with BRAF wild-type stage III and IV melanoma, there is an urgent clinical need to identify prognostic biomarkers and biomarkers predictive of treatment response. Circulating tumor DNA (ctDNA)...
5.
Bonazzi V, Aoude L, Brosda S, Bradford J, Lonie J, Loffler K, et al.
Asia Pac J Clin Oncol
. 2023 Jul;
21(1):77-86.
PMID: 37415393
Aim: The 5-year survival rate of pancreatic ductal adenocarcinoma (PDAC) is approximately 11% and has only improved marginally over the last three decades. For operable PDAC, resection and adjuvant FOLFIRINOX...
6.
Lonie J, Barbour A, Dolcetti R
Cancer Treat Rev
. 2021 May;
98:102219.
PMID: 33993033
With an incidence that is constantly rising, oesophageal adenocarcinoma (OAC) is becoming an increasing health burden worldwide. Although significant advances in treatment regimens have improved patient outcomes, survival rates for...
7.
Aoude L, Bonazzi V, Brosda S, Patel K, Koufariotis L, Oey H, et al.
Sci Rep
. 2020 Oct;
10(1):17687.
PMID: 33077847
Patients with late stage resected cutaneous melanoma have poor overall survival (OS) and experience irreversible adverse events from systemic therapy. There is a clinical need to identify biomarkers to predict...
8.
Croese A, Lonie J, Trollope A, Vangaveti V, Ho Y
Int J Surg
. 2018 Jun;
56:234-241.
PMID: 29936195
Aim: To summarize the reported prevalence and causative factors of Low Anterior Resection Syndrome (LARS) from studies using the LARS score. Methods: A systematic literature search was conducted using Pubmed,...